Molecular and Cellular Advances in Endometriosis Research: Paving the Way for Future Directions

Laganà, Antonio Simone; Ferrari, Federico; Mangione, Donatella; Fiorino, Fabio; Vassiliadis, Alessandra; Venezia, R

doi:10.3390/ijms241612663

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 Control of pain and improvement of quality of life (QoL) are the primary goals of the treatment, and an effective, safe, and well-tolerated therapy, suitable for long-term use, is fundamental. 1 …”

Section: Discussionmentioning

confidence: 99%

“…Endometriosis is a benign, chronic inflammatory condition characterized by endometrial tissue outside the uterus, and the etiology is probably multifactorial. 1 Endometriosis often causes pain, dysmenorrhea, dyspareunia, non-cyclical pelvic pain, and infertility disorders. 2 Almost 10% of women in reproductive age are diagnosed with ovarian endometriomas (OMAs), that is, localization of endometriosis in the ovaries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery

Ferrari,

Epis,

Casarin

et al. 2024

Womens Health (Lond Engl)

Self Cite

View full text Add to dashboard Cite

Background: Almost 10% of women in reproductive age are diagnosed with ovarian endometriomas and can experience symptoms and infertility disorders. Ovarian endometriomas can be treated with medical or surgical therapy. Objective: To assess whether long-term therapy with dienogest or oral cyclic estrogen-progestogens is effective in reducing the size of ovarian endometriomas, alleviating associated symptoms, and reducing the requirement for surgery. Design: Prospective non-interventional cohort study. Methods: We enrolled childbearing women diagnosed with ovarian endometriomas. We collected demographic, clinical, and surgical data, including the evaluation of ovarian endometrioma-associated symptoms and pain using the visual analog scale. We grouped the women according to treatment regimen into dienogest, estrogen-progestogens, and no-treatment. Patient’s assessment was performed at baseline and after 12 months evaluating the largest ovarian endometrioma diameter (in millimeters) and the associated symptoms. Furthermore, we analyzed the impact of hormonal treatment in a sub-group of women fulfilling at baseline the criteria for a first-line surgical approach (ovarian endometrioma > 30 mm with visual analog scale > 8 or ovarian endometrioma > 40 mm before assisted reproductive treatments or any ovarian endometrioma(s) > 60 mm). Results: We enrolled 142 patients: 62, 38, and 42 in dienogest, estrogen-progestogens, and no-treatment groups, respectively. No significant differences were found regarding baseline characteristics. After 12 months, the mean largest ovarian endometrioma diameter increased in the no-treatment group (31.1 versus 33.8; p < 0.01), while a significant reduction was registered in the dienogest (35.1 versus 25.8; p < 0.01) and estrogen-progestogens (28.4 versus 16.7; p < 0.01) groups; no significant difference in ovarian endometrioma diameter reduction between these two latter groups was noted (p = 0.18). Ovarian endometrioma-associated symptoms and pain improved in dienogest and estrogen-progestogens groups, with a significantly greater effect for dienogest than for estrogen-progestogens for dysmenorrhea (74% versus 59%; p < 0.01). In the sub-group of women eligible for first-line surgery at baseline, long-term treatment with dienogest and estrogen-progestogens reduced surgical eligibility by 30%. Conclusions: Decreased mean largest ovarian endometriomas’diameter after 12 months and reduction of the need for surgical treatment by 30% were observed in dienogest and estrogen-progestogens groups. Long-term treatment with dienogest had a greater effect in alleviating dysmenorrhea and pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery

Ferrari,

Epis,

Casarin

et al. 2024

Womens Health (Lond Engl)

Self Cite

View full text Add to dashboard Cite

show abstract

Molecular and Cellular Advances in Endometriosis Research: Paving the Way for Future Directions

Abstract: Molecular and cellular research in the field of endometriosis is moving forward in giant steps [...]

Cited by 1 publication

References 17 publications

Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery

Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery

Contact Info

Product

Resources

About